日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer

卡博替尼联合伊匹木单抗/纳武利尤单抗治疗既往接受过治疗的晚期分化型甲状腺癌患者

Konda, Bhavana; Sherman, Eric J; Massarelli, Erminia; Nieva, Jorge; Muzaffar, Jameel; Morris, John C 3rd; Ryder, Mabel; Ho, Alan L; Agulnik, Mark; Wei, Lai; Handley, Demond; Moses, Catherine; Jacob, Rajani; Wright, John; Streicher, Howard; Carson, William; Shah, Manisha H

Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype

端粒延长基因的种系变异易导致一种综合征型乳头状甲状腺癌。

DeBoy, Emily A; Nicosia, Anna M; Liyanarachchi, Sandya; Iyer, Sheila S; Shah, Manisha H; Ringel, Matthew D; Brock, Pamela; Armanios, Mary

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

替莫唑胺或替莫唑胺联合卡培他滨治疗晚期胰腺神经内分泌肿瘤患者的随机研究(ECOG-ACRIN E2211)

Kunz, Pamela L; Graham, Noah T; Catalano, Paul J; Nimeiri, Halla S; Fisher, George A; Longacre, Teri A; Suarez, Carlos J; Martin, Brock A; Yao, James C; Kulke, Matthew H; Hendifar, Andrew E; Shanks, James C; Shah, Manisha H; Zalupski, Mark M; Schmulbach, Edmond L; Reidy-Lagunes, Diane L; Strosberg, Jonathan R; O'Dwyer, Peter J; Benson, Al B 3rd

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial

放射治疗联合紫杉醇加帕唑帕尼或安慰剂治疗间变性甲状腺癌(NRG/RTOG 0912):一项随机、双盲、安慰剂对照、多中心 II 期试验

Sherman, Eric J; Harris, Jonathan; Bible, Keith C; Xia, Ping; Ghossein, Ronald A; Chung, Christine H; Riaz, Nadeem; Gunn, G Brandon; Foote, Robert L; Yom, Sue S; Wong, Stuart J; Koyfman, Shlomo A; Dzeda, Michael F; Clump, David A; Khan, Saad A; Shah, Manisha H; Redmond, Kevin; Torres-Saavedra, Pedro A; Le, Quynh-Thu; Lee, Nancy Y

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

纳武利尤单抗联合替莫唑胺治疗神经内分泌肿瘤的II期临床试验

Owen, Dwight H; Benner, Brooke; Wei, Lai; Sukrithan, Vineeth; Goyal, Ashima; Zhou, Ye; Pilcher, Carly; Suffren, Sheryl-Ann; Christenson, Gwen; Curtis, Nancy; Jukich, Megan; Schwarz, Emily; Savardekar, Himanshu; Norman, Ruthann; Ferguson, Sarah; Kleiber, Barbara; Wesolowski, Robert; Carson, William E; Otterson, Gregory A; Verschraegen, Claire F; Shah, Manisha H; Konda, Bhavana

A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors

贝伐珠单抗联合替西罗莫司治疗晚期胰外神经内分泌肿瘤的II期研究

Abuzakhm, Sonia M; Sukrithan, Vineeth; Fruth, Briant; Qin, Rui; Strosberg, Jonathan; Hobday, Timothy J; Semrad, Thomas; Reidy-Lagunes, Diane; Kindler, Hedy Lee; Kim, George P; Knox, Jennifer J; Kaubisch, Andreas; Villalona-Calero, Miguel; Chen, Helen; Erlichman, Charles; Shah, Manisha H

Kinase inhibitors in thyroid cancers

甲状腺癌中的激酶抑制剂

Sukrithan, Vineeth; Jain, Prachi; Shah, Manisha H; Konda, Bhavana

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial

达拉非尼对比达拉非尼+曲美替尼治疗BRAF突变放射性碘难治性分化型甲状腺癌:一项随机、2期、开放标签多中心试验的结果

Busaidy, Naifa L; Konda, Bhavana; Wei, Lai; Wirth, Lori J; Devine, Catherine; Daniels, Gregory A; DeSouza, Jonas A; Poi, Ming; Seligson, Nathan D; Cabanillas, Maria E; Sipos, Jennifer A; Ringel, Matthew D; Eisfeld, Ann-Kathrin; Timmers, Cynthia; Shah, Manisha H

Oxidative Stress and the Role of NADPH Oxidase in Glaucoma

氧化应激和 NADPH 氧化酶在青光眼中的作用

Fan Gaskin, Jennifer C; Shah, Manisha H; Chan, Elsa C

Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database

胃肠胰神经内分泌肿瘤手术切除后的复发模式:来自美国国家综合癌症网络肿瘤预后数据库的分析

Chan, Hilary; Zhang, Li; Choti, Michael A; Kulke, Matthew; Yao, James C; Nakakura, Eric K; Bloomston, Mark; Benson, Al B; Shah, Manisha H; Strosberg, Jonathan R; Bergsland, Emily K; Van Loon, Katherine